Mariola Vazquez-Martinez

8PUBLICATIONS
63CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)Molecular targetsTe urupare me te whai wāhi Māori ki te mātauranga (Māori responsiveness and engaged education)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

Aimaz Afrough, Danai Dima, Beatrice Razzo

|Aug 01, 2025
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

Binod Dhakal, Othman S Akhtar, David Fandrei

|Jul 09, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

|Jun 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Danai Dima, Mariola A Vazquez-Martinez, James A Davis

|May 09, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Oren Pasvolsky, Danai Dima, Lei Feng

|Apr 08, 2025
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.

Danai Dima, Aimaz Afrough, Utkarsh Goel

Pageof 2

Frequent Collaborators

8 joint publications

Surbhi Sidana

8 joint publications

Rahul Banerjee

8 joint publications

Krina K Patel

7 joint publications

James A Davis